Tevogen Bio HoldingsTVGN
TVGN
$0.4400
1.71%
Market Cap: $75.1M
About: Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Employees: 17
0
Funds holding %
of 6,710 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2,200% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 1
440% more funds holding
Funds holding: 5 [Q1] → 27 (+22) [Q2]
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.74% less ownership
Funds ownership: 4.14% [Q1] → 3.4% (-0.74%) [Q2]
91% less capital invested
Capital invested by funds: $30.7M [Q1] → $2.89M (-$27.8M) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for TVGN.